Marker rescue of the host range restriction defects of modified vaccinia virus Ankara

Virology

Volumn 251, Issue 2, 1998, Pages 334-342

  Wyatt, Linda S ^a   Carroll, Miles W ^a   Czerny, Claus Peter ^a   Merchlinsky, Michael ^b   Sisler, Jerry R ^a   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; ATTENUATION; CELL CULTURE; CHICK EMBRYO; EMBRYO; GENE DELETION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS DNA CELL DNA INTERACTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANKARA;

EID: 0032567049     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9397     Document Type: Article

References (46)

1. Ali A. N., Turner P. C., Brooks M. A., Moyer R. W. The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation. Virology. 202:1994;305-314.
2. Altenburger W., Süter C.-P., Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch. Virol. 105:1989;15-27.
3. Antoine G., Scheiflinger F., Dorner F., Falkner F. G. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses. Virology. 244:1998;365-396.
4. Archard L. C., Mackett M., Barnes D. E., Dumbell K. R. The genome structure of cowpox virus white pock variants. J. Gen. Virol. 65:1984;875-876.
5. Beattie E., Kauffman E. B., Martinez H., Perkus M. E., Jacobs B. I., Paoletti E., Tartaglia J. Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes. 12:1996;89-94.
6. Belyakov I. M., Wyatt L. S., Ahlers J. D., Earl P., Pendleton D., Kelsall B. L., Strober W., Moss B., Berzofsky J. A. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72:1998;8264-8272.
7. Bender B. S., Rowe C. A., Taylor F., Wyatt L. S., Moss B., Small P. A. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70:1996;6418-6424.
8. Blanchard T. J., Alcami A., Andrea P., Smith G. L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. J. Gen. Virol. 79:1998;1159-1167.
9. Brooks M. A., Ali A. N., Turner P. C., Moyer R. W. A rabbitpox virus serpin gene controls host range by inhibiting apoptosis in restrictive cells. J. Virol. 69:1995;7688-7698.
10. Carroll M., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 238:1997;198-211.
11. Carroll M. W., Overwiijk W. W., Chamberlain R. S., Rosenberg S. A., Moss B., Restifo N. P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model. Vaccine. 15:1997;387-394.
12. Chang H.-W., Uribe L. H., Jacobs B. L. Rescue of vaccinia virus lacking the E3L gene by mutants of E3L. J. Virol. 69:1995;6605-6608.
13. Chang H. W., Watson J. C., Jacobs B. L. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 89:1992;4825-4829.
14. Drexler I., Heller K., Wahren B., Erfle V., Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:1998;347-352.
15. Durbin A., Wyatt L. S., Slew J., Moss B., Murphy B. R. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine. 16:1998;1324-1330.
16. Earl P. L., Cooper N., Moss B. Preparation of cell cultures and vaccinia virus stocks. Current Protocols in Molecular Biology. 1991;Greene Publishing Associates & Wiley Interscience, New York. p. 16.16.1-16.16.7.
17. Esposito J. J., Cabradilla C. D., Nakano J. H., Obijeski J. F. Intragenomic sequence transposition in monkeypox virus. Virology. 109:1981;231-240.
18. Gillard S., Spehner D., Drillien R. Mapping of a vaccinia virus host range sequence by insertion into the viral thymidine kinase gene. J. Virol. 53:1985;316-318.
19. Goebel S. J., Johnson G. P., Perkus M. E., Davis S. W., Winslow J. P., Paoletti E. The complete DNA sequence of vaccinia virus. Virology. 179:1990;247-266.
20. Hanke T., Blanchard T. J., Schneider J., Ogg G. S., Tan R., Becker M., Gilbert S. C., Hill A. V., Smith G. L., McMichael A. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J. Gen. Virol. 79:1998;83-90.
21. Hirsch V. M., Fuerst T. R., Sutter G., Carroll M. W., Yang L. C., Goldstein S., Piatak M. Jr., Elkins W. R., Alvord W. G., Montefiori D. C., Moss B., Lifson J. D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:1996;3741-3752.
22. Hochstein-Mintzel V., Huber H. C., Stickl H. Virulenz und Immunogenität eines modifizierten Vaccinia-virus (Stamm MVA). Z. Immun.-Forsch. 144:1972;140-145.
23. Ink B. S., Gilbert C. S., Evan G. I. Delay of vaccinia virus-induced apoptosis in nonpermisive hamster ovary cells by the cowpox virusCHOhrE1B 19K. J. Virol. 69:1995;661-668.
24. Kotwal G. J., Moss B. Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant. Virology. 167:1988;524-537.
25. Kotwal G. J., Moss B. Vaccinia virus encodes two proteins that are structurally related to members of the plasma serine protease inhibitor superfamily. J. Virol. 63:1989;600-606.
26. Mahnel H., Mayr A. Erfahrungen bei der Schutzimpfung gegen Orthopocken von Mensch und Tier mit dem Impfstamm MVA. Berl. Munch. Tierarzt. Wschr. 107:1994;253-256.
27. Mayr A., Hochstein-Mintzel V., Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-stammes MVA. Infection. 3:1975;6-14.
28. Mayr A., Stickl H., Müller H. K., Danner K., Singer H. Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung under Verhalten im abwehrgeschwächten Organismus. Zbl. Bakt. Hyg. 167:1978;375-390.
29. Merchlinsky M., Moss B. Resolution of vaccinia virus DNA concatemer junctions requires late gene expression. J. Virol. 63:1989;1595-1603.
30. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1991;1031-1038.
31. Njayou M., Drillien R., Kirn A. Characteristics of the inhibition of protein synthesis by vaccinia virus in nonpermissive Chinese hamster ovary cells. Ann. Virol. 133:1982;393-402.
32. Oguiura N., Spehner D., Drillien R. Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. J. Gen. Virol. 74:1993;1409-1413.
33. Perkus M. E., Goebel S. J., Davis S. W., Johnson G. P., Limbach K., Norton E. K., Paoletti E. Vaccinia virus host range genes. Virology. 179:1990;276-286.
34. Ramsey-Ewing A., Moss B. Restriction of vaccinia virus replication in CHO cells occurs at the stage of viral intermediate protein synthesis. Virology. 106:1995;984-993.
35. Ramsey-Ewing A. L., Moss B. Complementation of a vaccinia virus host range K1L gene deletion by the non-homologous CP77 gene. Virology. 222:1996;75-86.
36. +. Nat. Med. 4:1998;397-402.
37. Seth A., Ourmanov I., Kuroda M. J., Schmitz J. E., Carroll M. W., Wyatt L. S., Moss B., Forman M. A., Hirsch V. M., Letvin N. L. Recombinant MVA-SIVgag pol. Proc. Natl. Acad. Sci. USA. 95:1998;10112-10116.
38. Shchelkunov S. N., Safronov P. F., Totmenin A. V., Petrov N. A., Ryazankina O. I., Gutorov V. V., Kotwal G. J. The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. Virology. 243:1998;432-460.
39. Smith G. L., Howard S. T., Chan T. S. Vaccinia virus encodes a family of genes with homology to serine protease inhibitors. J. Gen. Virol. 70:1989;2333-2343.
40. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H. C., Schäfer H., Holzner A. MVA-Stufenimpfung gegen Pocken: Klinische Erprobung des attenuierten Pocken-Lebendimpfstoffes, Stamm MVA. Dtsch. Med. Wschr. 99:1974;2386-2392.
41. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA. 89:1992;10847-10851.
42. Sutter G., Ohlmann M., Erfle V. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett. 371:1995;9-12.
43. Sutter G., Wyatt L. S., Foley P. L., Bennink J. R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 12:1994;1032-1040.
44. Thompson C. L., Condit R. C. Marker rescue mapping of vaccinia virus temperature-sensitive mutants using overlapping cosmid clones representing the entire virus genome. Virology. 150:1986;10-20.
45. Wyatt L. S., Moss B., Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology. 210:1995;202-205.
46. Wyatt L. S., Shors S. T., Murphy B. R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine. 14:1996;1451-1458.